- Home
- / Satellos Bioscience
Satellos Bioscience
Satellos Bioscience Summary
Company Summary
- Overview
- Satellos Bioscience is a biotechnology company developing medicines to treat degenerative muscle diseases. It provides research in muscle stem cell polarity that is applied to a discovery platform, MyoReGenXTM. The company’s product is an oral, small molecule drug candidate as a disease-modifying treatment for Duchenne muscular dystrophy.
- Type
- Public
- Status
- Active
- Founded
- 2018
- HQ
- Toronto, CA | view all locations
- Website
- https://www.satellos.com
- Cybersecurity rating
Table of Contents
Key People
Geoff MacKay, Chair, Board of Directors
Elizabeth Williams, Chief Financial Officer
Frank Gleeson, Co-Founder, Chief Executive Officer, Board Member
LocationsView all
1 location detected
Toronto, ON HQ
Canada
201-65 Front St E
Satellos Bioscience Financials
Summary Financials
- Net income (FY, 2025)
- ($24.9M)
- Cash (FY, 2025)
- $4.4M
- EBIT (FY, 2025)
- ($24.1M)